https://www.biopharmawatch.com/news/TXG/10x-genomics-patent-infringement-verdict-parse-biosciences BiopharmaWatch en 2026-08-28T18:38:00.000Z 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences https://www.biopharmawatch.com/news/UNH/am-best-affirms-unitedhealth-group-credit-ratings BiopharmaWatch en 2026-08-28T18:27:00.000Z AM Best Affirms Credit Ratings of UnitedHealth Group Incorporated and Its Subsidiaries https://www.biopharmawatch.com/news/NTRA/natera-susan-g-komen-partnership-breast-cancer BiopharmaWatch en 2026-08-28T15:03:00.000Z Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-phase-1a-data-ctx310-esc-2026 BiopharmaWatch en 2026-08-28T14:31:00.000Z CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 https://www.biopharmawatch.com/news/AGEN/agenus-bot-bal-survival-mss-colorectal-cancer BiopharmaWatch en 2026-08-28T14:07:00.000Z Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism https://www.biopharmawatch.com/news/NTHI/neonc-phase-2a-success-registration-pathway BiopharmaWatch en 2026-08-28T14:07:00.000Z NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger https://www.biopharmawatch.com/news/IGC/ascendiant-capital-markets-raises-igc-pharma-price-target BiopharmaWatch en 2026-08-28T13:40:00.000Z Ascendiant Capital Markets Raises IGC Pharma Price Target to $6.00, Citing CALMA Progress and Q4 2026 Topline Catalyst https://www.biopharmawatch.com/news/COSM/cosmos-health-strengthens-balance-sheet-capital-structure BiopharmaWatch en 2026-08-28T13:30:00.000Z Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions https://www.biopharmawatch.com/news/TNON/tenon-medical-3m-private-placement-offering BiopharmaWatch en 2026-08-28T13:00:00.000Z WallachBeth Capital Announces Tenon Medical Pricing of $3M Private Placement Offering https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-south-palm-cardiovascular-agreements BiopharmaWatch en 2026-08-28T12:45:00.000Z Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-approvals-2026-2027 BiopharmaWatch en 2026-08-28T12:30:00.000Z Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season https://www.biopharmawatch.com/news/LH/labcorp-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-08-28T12:30:00.000Z Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/IVF/invo-fertility-hc-wainwright-conference-2026 BiopharmaWatch en 2026-08-28T12:30:00.000Z INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/AMRN/reduce-it-legacy-analysis-esc-congress-2026 BiopharmaWatch en 2026-08-28T12:15:29.000Z New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-expands-intellectual-property-portfolio BiopharmaWatch en 2026-08-28T12:15:00.000Z Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-investor-conferences-2026 BiopharmaWatch en 2026-08-28T12:00:00.000Z Minerva Neurosciences to Participate in Two Upcoming Investor Conferences https://www.biopharmawatch.com/news/FEED/envue-medical-reverse-stock-split BiopharmaWatch en 2026-08-28T12:00:00.000Z ENvue Medical, Inc. Announces 1-for-12 Reverse Stock Split https://www.biopharmawatch.com/news/BLRX/biolinerx-announces-375-million-offering BiopharmaWatch en 2026-08-28T12:00:00.000Z BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-public-offering-120-million BiopharmaWatch en 2026-08-28T11:30:00.000Z Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering https://www.biopharmawatch.com/news/IBIO/ibio-fiscal-year-2026-results-corporate-update BiopharmaWatch en 2026-08-28T11:00:00.000Z iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/UTHR/united-therapeutics-data-esc-ers-congress-2026 BiopharmaWatch en 2026-08-28T11:00:00.000Z United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026 https://www.biopharmawatch.com/news/XRTX/xortx-terminates-investor-relations-program BiopharmaWatch en 2026-08-28T11:00:00.000Z XORTX Announces Termination and Postponement of Investor Relations Program https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-private-placement-financing BiopharmaWatch en 2026-08-28T10:00:00.000Z Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million https://www.biopharmawatch.com/news/IMRN/immuron-fy26-preliminary-results BiopharmaWatch en 2026-08-28T10:00:00.000Z Immuron Reports FY26 Preliminary Results https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-asset-sale-teva-pharmaceuticals BiopharmaWatch en 2026-08-28T10:00:00.000Z BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-positive-interim-data-netherton-syndrome BiopharmaWatch en 2026-08-28T10:00:00.000Z Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome https://www.biopharmawatch.com/news/CYTK/cytokinetics-positive-results-acacia-hcm-esc-2026 BiopharmaWatch en 2026-08-28T09:45:00.000Z Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine https://www.biopharmawatch.com/news/SLBT/sl-science-fda-drug-master-file-gdt-exosomes BiopharmaWatch en 2026-08-28T07:53:03.000Z SL Science 宣布新進展：GDT細胞衍生外泌體，取得 FDA 藥物主檔案登記 https://www.biopharmawatch.com/news/HTFL/heartflow-ffrct-analysis-reduces-invasive-procedures BiopharmaWatch en 2026-08-28T06:48:00.000Z Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half https://www.biopharmawatch.com/news/PHG/philips-imricor-mri-interventional-lab-solution BiopharmaWatch en 2026-08-28T06:46:00.000Z Riassunto: Philips e Imricor lanciano una soluzione per laboratorio di risonanza magnetica interventistica cardiaca, ampliando la loro collaborazione di lunga data https://www.biopharmawatch.com/news/PHG/philips-imricor-interventional-mri-lab-solution BiopharmaWatch en 2026-08-28T06:44:00.000Z Philips et Imricor lancent une solution de laboratoire d'IRM interventionnelle cardiaque, renforçant ainsi leur collaboration de longue date https://www.biopharmawatch.com/news/PHG/philips-imricor-mr-laboratory-solution-launch BiopharmaWatch en 2026-08-28T02:07:00.000Z Samenvatting: Philips en Imricor lanceren een MR-laboratoriumoplossing voor hartingrepen en breiden daarmee hun langdurige samenwerking uit https://www.biopharmawatch.com/news/GILD/fda-approves-gileads-bixlenvo-hiv-treatment BiopharmaWatch en 2026-08-27T21:47:00.000Z U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens https://www.biopharmawatch.com/news/SGP/spyglass-pharma-irvine-headquarters-opening BiopharmaWatch en 2026-08-27T20:40:00.000Z SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space https://www.biopharmawatch.com/news/BNTX/pfizer-biontech-fda-approval-xfg-covid-vaccine BiopharmaWatch en 2026-08-27T20:30:29.000Z Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine https://www.biopharmawatch.com/news/PFE/pfizer-biontech-fda-approval-xfg-covid-vaccine BiopharmaWatch en 2026-08-27T20:30:00.000Z Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine https://www.biopharmawatch.com/news/IQV/iqvia-awards-ai-technology-innovation BiopharmaWatch en 2026-08-27T20:15:00.000Z IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare https://www.biopharmawatch.com/news/IMCC/im-cannabis-shares-trading-consolidated-basis BiopharmaWatch en 2026-08-27T20:10:00.000Z IM Cannabis Shares Commence Trading on 30:1 Consolidated Basis https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-public-offering BiopharmaWatch en 2026-08-27T20:09:00.000Z Kazia Therapeutics Limited Announces Proposed Public Offering https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-promotes-nick-smith-president-cfo BiopharmaWatch en 2026-08-27T20:05:00.000Z Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer https://www.biopharmawatch.com/news/QGEN/qiagen-launches-qiaysymphony-connect-nucleic-acid-extraction BiopharmaWatch en 2026-08-27T20:05:00.000Z QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction https://www.biopharmawatch.com/news/AGL/agilon-health-revised-presentation-time-jefferies-conference BiopharmaWatch en 2026-08-27T20:05:00.000Z agilon health Announces Revised Presentation Time at the 2026 Jefferies Healthcare Services and Technology Conference https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-appoints-kevin-lundquist-cfo BiopharmaWatch en 2026-08-27T20:05:00.000Z Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™ https://www.biopharmawatch.com/news/RMD/resmed-participation-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-08-27T20:05:00.000Z Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-paxalisib-triple-negative-breast-cancer BiopharmaWatch en 2026-08-27T20:01:00.000Z Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer https://www.biopharmawatch.com/news/HTFL/heartflow-wells-fargo-healthcare-conference-2026 BiopharmaWatch en 2026-08-27T20:01:00.000Z Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/ACET/adicet-bio-fda-clearance-adi-212 BiopharmaWatch en 2026-08-27T20:00:00.000Z Adicet Bio Announces FDA Clearance of IND Application for ADI-212 https://www.biopharmawatch.com/news/ROIV/roivant-fda-approval-lisraya-dermatomyositis BiopharmaWatch en 2026-08-27T19:29:00.000Z Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. https://www.biopharmawatch.com/news/PHG/philips-imricor-interventional-mr-lab-solution BiopharmaWatch en 2026-08-27T19:27:00.000Z Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration https://www.biopharmawatch.com/news/SYK/stryker-participate-2026-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-27T19:00:00.000Z Stryker to participate in the 2026 Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/ALGS/alg-055009-phase-2a-trial-non-cirrhotic-adults BiopharmaWatch en 2026-08-27T17:37:32.000Z ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial https://www.biopharmawatch.com/news/WAT/letsgetchecked-fuze-health-waters-hpv-screening-tool BiopharmaWatch en 2026-08-27T14:00:00.000Z LetsGetChecked Powered by Fuze Health Partners with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-names-six-broker-dealers-lawsuit BiopharmaWatch en 2026-08-27T13:27:00.000Z Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit https://www.biopharmawatch.com/news/QDEL/faster-answers-better-decisions-adlm-2026-highlights BiopharmaWatch en 2026-08-27T13:12:00.000Z Faster Answers, Better Decisions: ADLM 2026 Highlights https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-virtual-investor-conference BiopharmaWatch en 2026-08-27T13:06:29.000Z CNS Pharmaceuticals Participates in the Virtual Investor “Why Now” On-Demand Conference https://www.biopharmawatch.com/news/MYGN/myriad-genetics-presentation-wells-fargo-conference-2026 BiopharmaWatch en 2026-08-27T13:05:00.000Z Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/MBRX/moleculin-ceo-participates-virtual-investor-conference BiopharmaWatch en 2026-08-27T13:01:23.000Z Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference https://www.biopharmawatch.com/news/DARE/dare-bioscience-ceo-participates-virtual-investor-series BiopharmaWatch en 2026-08-27T13:01:00.000Z Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-virtual-investor-conference BiopharmaWatch en 2026-08-27T13:01:00.000Z Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference https://www.biopharmawatch.com/news/GRI/gri-bio-why-now-video-webcast BiopharmaWatch en 2026-08-27T13:01:00.000Z GRI Bio Featured in "Why Now" On-Demand Video Webcast https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-virtual-investor-conference BiopharmaWatch en 2026-08-27T13:01:00.000Z Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-ceo-bob-jahr-virtual-investor-conference BiopharmaWatch en 2026-08-27T13:01:00.000Z Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference https://www.biopharmawatch.com/news/AIM/aim-immunotech-participates-virtual-investor-conference BiopharmaWatch en 2026-08-27T13:01:00.000Z AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference https://www.biopharmawatch.com/news/CELU/celularity-musecell-us-manufacturing-collaboration BiopharmaWatch en 2026-08-27T13:00:00.000Z Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-hemodiafiltration-study BiopharmaWatch en 2026-08-27T13:00:00.000Z Fresenius Medical Care Announces Publication of a Multinational Real-World Evidence Study Associating High-Volume Hemodiafiltration with Lower Mortality Risk Than Conventional Hemodialysis https://www.biopharmawatch.com/news/CVS/cvs-pharmacy-minuteclinic-offering-updated-flu-vaccines BiopharmaWatch en 2026-08-27T13:00:00.000Z CVS Pharmacy® and MinuteClinic® now offering updated flu vaccines nationwide https://www.biopharmawatch.com/news/CALC/calcimedica-reverse-stock-split-2026 BiopharmaWatch en 2026-08-27T13:00:00.000Z CalciMedica Announces One-for-Five Reverse Stock Split https://www.biopharmawatch.com/news/FBRX/argenx-completes-acquisition-forte-biosciences BiopharmaWatch en 2026-08-27T12:50:00.000Z argenx Completes Acquisition of Forte Biosciences, Inc. https://www.biopharmawatch.com/news/CAI/caris-ai-guided-therapy-pancreatic-cancer-study BiopharmaWatch en 2026-08-27T12:30:00.000Z Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer https://www.biopharmawatch.com/news/PRGO/perrigo-attend-barclays-global-consumer-conference BiopharmaWatch en 2026-08-27T12:30:00.000Z Perrigo to Attend the Barclays Global Consumer Conference https://www.biopharmawatch.com/news/FBLG/fibrobiologics-cyw628-phase-1-2-trial-update BiopharmaWatch en 2026-08-27T12:30:00.000Z FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-preclinical-pancreatic-cancer-data BiopharmaWatch en 2026-08-27T12:30:00.000Z Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-hc-wainwright-conference-2026 BiopharmaWatch en 2026-08-27T12:30:00.000Z Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/BMRA/biomerica-announces-2-23-million-financing BiopharmaWatch en 2026-08-27T12:19:00.000Z Biomerica Announces $2.23 Million Financing https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-2026-cantor-conference BiopharmaWatch en 2026-08-27T12:05:00.000Z Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference https://www.biopharmawatch.com/news/BHC/bausch-health-2026-aspire-higher-scholarship-winners BiopharmaWatch en 2026-08-27T12:02:00.000Z Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-reverse-stock-split BiopharmaWatch en 2026-08-27T12:00:00.000Z Glucotrack, Inc. Announces Reverse Stock Split https://www.biopharmawatch.com/news/ARDT/ardent-health-wells-fargo-conference-2026 BiopharmaWatch en 2026-08-27T12:00:00.000Z Ardent Health to Participate in the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/XTNT/xtant-medical-biohorizons-partnership-prolifica BiopharmaWatch en 2026-08-27T12:00:00.000Z Xtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Market https://www.biopharmawatch.com/news/ENTX/entera-participate-fall-investor-conferences BiopharmaWatch en 2026-08-27T12:00:00.000Z Entera to Participate in Upcoming Fall Investor Conferences https://www.biopharmawatch.com/news/PLUR/pluri-announces-3-3-million-offering BiopharmaWatch en 2026-08-27T12:00:00.000Z Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor https://www.biopharmawatch.com/news/VRCA/verrica-completes-enrollment-cove-2-trial-ychant BiopharmaWatch en 2026-08-27T12:00:00.000Z Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027 https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-esc-congress-2026-psvt-impact BiopharmaWatch en 2026-08-27T12:00:00.000Z Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes https://www.biopharmawatch.com/news/HQY/healthequity-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-27T12:00:00.000Z HealthEquity Reports Second Quarter Ended July 31, 2026 Financial Results https://www.biopharmawatch.com/news/MBX/mbx-biosciences-phase-3-optimize-trial-canjuparatide BiopharmaWatch en 2026-08-27T12:00:00.000Z MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism https://www.biopharmawatch.com/news/CTMX/cytomx-fda-fast-track-varseta-m-colorectal-cancer BiopharmaWatch en 2026-08-27T12:00:00.000Z CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) https://www.biopharmawatch.com/news/SLBT/sl-science-fda-drug-master-file-gdt-exosomes BiopharmaWatch en 2026-08-27T12:00:00.000Z SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform https://www.biopharmawatch.com/news/VTAK/catheter-precision-commercial-milestones-vtak BiopharmaWatch en 2026-08-27T12:00:00.000Z Catheter Precision Achieves Major Commercial Milestones with Cardinal Health, Johns Hopkins and the placement of the First VIVO System in Germany https://www.biopharmawatch.com/news/ALVO/alvotech-investor-conferences-september-2026 BiopharmaWatch en 2026-08-27T12:00:00.000Z Alvotech to present at upcoming investor conferences in September https://www.biopharmawatch.com/news/USPH/us-physical-therapy-midwest-ideas-conference-2026 BiopharmaWatch en 2026-08-27T11:30:00.000Z U.S. Physical Therapy Presented at the 17th Annual Midwest Ideas Conference https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-soquelitinib-phase-1-data BiopharmaWatch en 2026-08-27T11:30:00.000Z Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial https://www.biopharmawatch.com/news/BWAY/brainsway-deep-tms-suicidal-ideation-reduction BiopharmaWatch en 2026-08-27T11:30:00.000Z BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation https://www.biopharmawatch.com/news/NXL/nexalin-technology-reverse-stock-split BiopharmaWatch en 2026-08-27T11:25:00.000Z Nexalin Technology Announces Reverse Stock Split https://www.biopharmawatch.com/news/HLF/herbalife-fireside-chat-barclays-global-consumer-conference BiopharmaWatch en 2026-08-27T11:05:00.000Z Herbalife to Participate in Fireside Chat at Barclays Global Consumer Conference on September 9 https://www.biopharmawatch.com/news/AVAH/aveanna-participate-deutsche-bank-healthcare-summit BiopharmaWatch en 2026-08-27T11:00:00.000Z Aveanna to Participate in the Deutsche Bank 2026 Healthcare Summit https://www.biopharmawatch.com/news/NBP/novabridge-biosciences-september-investor-conferences BiopharmaWatch en 2026-08-27T11:00:00.000Z NovaBridge Biosciences to Participate in September Investor Conferences https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-participate-2026-wells-fargo-conference BiopharmaWatch en 2026-08-27T10:50:00.000Z Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/NTRA/natera-angiex-collaboration-signatera-agx101 BiopharmaWatch en 2026-08-27T10:00:00.000Z Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™ https://www.biopharmawatch.com/news/AMGN/tezspire-positive-phase-3-results-eosinophilic-esophagitis BiopharmaWatch en 2026-08-27T06:00:00.000Z TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS https://www.biopharmawatch.com/news/ABBV/abbvie-submits-ema-application-skyrizi-crohns-disease BiopharmaWatch en 2026-08-27T06:00:00.000Z AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-upsized-private-offering-notes BiopharmaWatch en 2026-08-27T04:30:00.000Z Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases https://www.biopharmawatch.com/news/MESO/mesoblast-reports-revenue-growth-2026 BiopharmaWatch en 2026-08-27T00:32:00.000Z Mesoblast Reports Substantial Revenue Growth to US$120M https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-paxalisib-triple-negative-breast-cancer BiopharmaWatch en 2026-08-27T00:00:00.000Z Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively ... https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-public-offering BiopharmaWatch en 2026-08-27T00:00:00.000Z Kazia Therapeutics Limited Announces Proposed Public Offering Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively ... https://www.biopharmawatch.com/news/CUVL/clinuvel-nasdaq-listing-asx-delisting BiopharmaWatch en 2026-08-26T22:35:54.000Z CLINUVEL considers Nasdaq listing, ASX delisting https://www.biopharmawatch.com/news/CUVL/decade-profitability-clinuvel-us-expansion BiopharmaWatch en 2026-08-26T22:34:49.000Z A decade of profitability provides foundation for CLINUVEL’s U.S. expansion https://www.biopharmawatch.com/news/CUVL/clinuvel-appendix-4e-annual-report BiopharmaWatch en 2026-08-26T22:33:49.000Z Appendix 4E & Annual Report https://www.biopharmawatch.com/news/CUVL/clinuvel-investor-presentation-us-expansion BiopharmaWatch en 2026-08-26T22:32:49.000Z CLINUVEL Investor Presentation https://www.biopharmawatch.com/news/CUVL/appendix-4g-corporate-governance-statement BiopharmaWatch en 2026-08-26T22:32:00.000Z Appendix 4G and Corporate Governance Statement https://www.biopharmawatch.com/news/CUVL/dividend-distribution-cuv BiopharmaWatch en 2026-08-26T22:30:49.000Z Dividend/Distribution – CUV https://www.biopharmawatch.com/news/GMED/globus-medical-acquisition-higgs-boson-health BiopharmaWatch en 2026-08-26T21:57:00.000Z Globus Medical Announces Acquisition of Higgs Boson Health to Transform Healthcare Experience Through AI-Driven Digital Solutions https://www.biopharmawatch.com/news/IMRX/immuneering-fda-approval-pancreatic-cancer BiopharmaWatch en 2026-08-26T21:16:00.000Z Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients https://www.biopharmawatch.com/news/ALC/alcon-prices-eur-500-million-senior-notes-offering BiopharmaWatch en 2026-08-26T21:00:00.000Z Alcon Prices EUR 500 Million Senior Notes Offering https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-q4-fiscal-year-results BiopharmaWatch en 2026-08-26T20:20:00.000Z Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance https://www.biopharmawatch.com/news/NEO/neogenomics-medicare-coverage-radar-st-assay BiopharmaWatch en 2026-08-26T20:17:00.000Z NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring https://www.biopharmawatch.com/news/BDX/bd-presents-wells-fargo-healthcare-conference-2026 BiopharmaWatch en 2026-08-26T20:15:00.000Z BD to Present at Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-september-investor-conferences BiopharmaWatch en 2026-08-26T20:15:00.000Z First Tracks Biotherapeutics Announces Participation in September Investor Conferences https://www.biopharmawatch.com/news/RXST/rxsight-participate-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-26T20:15:00.000Z RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/A/agilent-reports-third-quarter-fiscal-year-2026-results BiopharmaWatch en 2026-08-26T20:05:00.000Z Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results https://www.biopharmawatch.com/news/EYE/national-vision-participation-barclays-consumer-conference BiopharmaWatch en 2026-08-26T20:05:00.000Z National Vision, Inc. Announces Participation in Barclays 19th Annual Global Consumer Conference https://www.biopharmawatch.com/news/CNMD/conmed-participate-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-26T20:05:00.000Z CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-investor-conferences-september-2026 BiopharmaWatch en 2026-08-26T20:05:00.000Z Arcus Biosciences to Participate in Three Upcoming Investor Conferences https://www.biopharmawatch.com/news/GILD/gilead-sciences-investor-conferences-september-2026 BiopharmaWatch en 2026-08-26T20:05:00.000Z Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences https://www.biopharmawatch.com/news/XENE/xenon-phase-3-x-tole2-eec-2026 BiopharmaWatch en 2026-08-26T20:01:00.000Z Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026 https://www.biopharmawatch.com/news/VRTX/vertex-upcoming-september-investor-conferences BiopharmaWatch en 2026-08-26T20:00:00.000Z Vertex to Participate in Upcoming September Investor Conferences